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Introduction: This study aimed to assess surgical workload and risk factors for gastrointestinal bleeding in
patients on warfarin admitted to a hospital.
Methods: Data was collected for all warfarinised patients admitted between April 2005 and October 2007
with gastrointestinal bleeding.
Results: A total of 30 patients (average 80 years) were recorded. Indications for warfarin therapy were
atrial ﬁbrillation (80%), mechanical heart valve (6.67%) and embolic disease (13.33%). Fifty percent were
admitted with an INR above therapeutic range and of these patients, 83% were on one or more
medications known to potentiate the anti-coagulation effect of warfarin. Nine patients were also taking
anti-platelet medication. Five of these nine had an admission INR within the intended therapeutic range.
Thirteen patients received blood transfusions and had a signiﬁcantly higher (p< 0.05) INR (average 9)
than the 17 patients not requiring transfusion (average 2.8). The average cost of transfusion per patient
was £470. None of the patients required acute surgical intervention. The average length of stay was 7
days, at a total cost of £1444 per patient. Investigations found the cause of bleeding to be diverticulosis in
9 patients and neoplastic disease in 4 patients. Almost half of the patients received no investigation due
to risks from co-morbidity.
Conclusions: Uncontrolled anti-coagulation, polypharmacy and age were overwhelming risk factors for
major gastrointestinal bleeding. Our results show that adding anti-platelet therapy has to be clearly
justiﬁed against the increased risk of bleeding. Cost to the surgical department was high and no patients
required surgical or radiological intervention.
What is already known about this topic?: Warfarin is an important drug, but the complications of its use
are difﬁcult and expensive to deal with. Warfarin use is a risk factor for haemorrhage, and this commonly
involves the gastrointestinal tract. The use of warfarin is set to increase as the population ages and atrial
ﬁbrillation and other cardiovascular risk factors become more prevalent. Consequently, one can expect
a rise in warfarin-related gastrointestinal haemorrhage.
What does this article add?: Our study aimed to assess the burden of gastrointestinal haemorrhage
secondary to warfarin on our surgical department (which was high), and also to assess what the risk
factors for haemorrhage for patients onwarfarin. One of the risk factors we uncovered was polypharmacy,
particularly involving anti-platelets e.g. aspirin. We highlight the need for further guidance with regards
to managing patients on warfarin, and suggest possible solutions to the problems uncovered.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.ay, London N14 7LT, United
ciates Ltd. Published by Elsevier Lt1. Introduction
The prevalence of atrial ﬁbrillation (AF) increases with age,
occurring in less than 1% of the population under 60 years and in
almost 10% of the population over 80 years.1 This is projected to rise
with an aging population and as the prevalence of cardiovascular risk
factors increases.2 AF is recognised as an independent risk factor for
stroke, increasing the risk by ﬁve-fold.3 Long-term anti-coagulationd. All rights reserved.
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stroke by approximately 65%.4 This compares to a more modest
reduction of 20% when aspirin is used alone.5 The National Institute
for Health and Clinical Excellence (NICE) guidelines for the
management of AF currently recommend the use of warfarin for the
prevention of thrombo-embolic stroke.6 This should be considered
against the annual risk of haemorrhage which is estimated at 9%.7
Most commonly, bleeding complications involve the gastrointestinal
(GI) tract8 and, invariably, patients are often categorised as part of
the surgical case-load.
The aims of our study were to establish the risk factors for
gastrointestinal bleeding in patients on warfarin therapy and to
assess surgical workload, cost and patient outcome in a single
district general hospital.
2. Methods
All the case notes of patients taking warfarin admitted to the
surgical assessment unit with gastrointestinal bleeding were
retrospectively reviewed over an 18-month period (April 2005–
October 2007). In our trust, any patient with upper gastrointestinal
bleeding is admitted to the surgical department if they are over the
age of 65. All lower GI bleeding is admitted to the surgical
department at any age.
For each patient, the following were recorded: gender, age, the
indication for warfarin therapy, discharge and admission interna-
tional normalised ration (INR), concomitant medications, blood
transfusion, any reversal agent requirement, investigations under-
taken, alcohol intake, liver function tests on admission, and the
total length of stay and cost of admission. All statistical compari-
sons were made using the Mann Whitney U test.
3. Results
A total of 30 patients were included in our study (16 females and
14males) with an average age of 80 years (range¼ 63–93 years). AF
was the indication for warfarin in 80% of patients with the
remainder either anti-coagulated for recurrent thrombo-embolic
events or metallic valve replacements. There were a wide range of
INRs on admission (average of 5.5), with half of the patients in our
study exceeding the target upper limit on admission (Fig. 1).0
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Fig. 1. Anti-coagulation at presentation. This table shows the range of INR on
presentation for patients in our study. For AF, therapeutic INR¼ 2–3; for metallic
valves,¼ 3–4.Thirteen patients (43.3%) required a blood transfusion. The
average admission INR of these patients was signiﬁcantly higher
than in those patients who didn’t require a transfusion (9 vs 2.8,
P¼ 0.02) (Fig. 2).
Fourteen patients required the use of a reversal agent in keeping
with the British Committee for Standards in Haematology.9 Patients
requiring a reversal agent had a signiﬁcantly higher INR compared
to those who did not (8.2 vs 2.9) (P¼ 0.014) (Fig. 3).
In thirty percent of our subjects (9 patients) it was not appro-
priate to carry out further investigation into the cause of their
bleeding due to their extensive co-morbidity. Lower gastrointestinal
studies were undertaken for the majority of patients (17 patients)
and 4 patients underwent upper endoscopy as appropriate to the
presentation (Fig. 4). Nine patients were diagnosed with divertic-
ular disease as the cause of their bleed and neoplastic disease was
the cause in four patients. In the remainder, no signiﬁcant cause
was found. Nopatient required surgical intervention or angiography
during their acute admission to stop their bleeding.
The length of stay ranged from 1 day to 21 days (average 7 days)
(Fig. 5). All patients were initially admitted to the Surgical Assess-
ment Unit at a cost of £325 per day. The cost for stay in a general
surgical ward is £190 per day giving an average cost of £1444 per
patient. The cost of 1 unit of blood in our trust is £139. The mean
number of units of blood used over all 30 patients was 3.4, at an
average cost of £430 per patient.
Eighty-three percent of the patients were on one or medications
which are known to potentiate the anti-coagulant effect of warfarin.
Examples of these were amiodarone, PPI’s, steroids, thyroxine
analgesics e.g. paracetemol, anti-microbials and diabetic medica-
tion e.g. gliclazide. Nine patients were on aspirin or clopidogrel, as
well as warfarin.
One patient had a weekly alcohol intake greater than 21 units.
We found that documentation of alcohol intake was poor; either
not quantiﬁed, or not recorded at all.
There was no signiﬁcant data collected regarding liver function
tests on admission for any of the patients.4. Discussion
Previous studies have identiﬁed age as a major risk factor for
gastrointestinal bleeding. This was conﬁrmed by our study with an
average age of 80 years. A prospective observational study by Hylek
et al showed that cumulative incidence of major haemorrhage in
patients over 80 years was 13.1 per 100 person-years. In patients
younger than 80, it was much less at 4.9. All the patients requiring
prothrombin complex – only indicated in major bleeds9 – in our
study were over the age of 80, again highlighting the risk of major
haemorrhage with increasing age. The risk of stroke, however, alsoBlood Transfusion No Transfusion
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Fig. 2. Transfusion requirements. 13 patients (43.3%) required transfusion. The INR of
these patients was signiﬁcantly higher¼ 9.06, as shown by this t-test.
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Fig. 3. Use of reversal agents. Vitamin K was the most commonly used reversal agent. Use of reversal agent was related to INR.
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of bleeding and stroke prevention.
Currently, the British Committee for Standards in Haematology
recommends that the INR is checked weekly after commencing
warfarin, until it is stable, it can then be checked less frequently. It
does not suggest that this should be done more frequently for
patients older than 80 years. Given the increased risk of major
haemorrhage, more regular monitoring of INR would perhaps be
beneﬁcial for this age group.
Polypharmacy is commonwith elderly patients. It is not unusual
for patients to be on medications that interact with warfarin. For
example, 7 patients in this studywere on amiodarone. Four of these
patients had INRs greater than 3.5 on presentation (3.5–6). Often
this polypharmacy is unavoidable – warfarin and amiodarone are
often both required in the management of atrial ﬁbrillation – and
temporary e.g. anti-microbials. The Committee also recommended
that patients on any medication which may interact with warfarin
should have their INR checked more regularly.9 The number of
supra-therapeutic INRs that might be secondary to drug interaction
in this study would suggest this is not always being done.
The use of anti-platelet agents i.e. aspirin and clopidogrel, in
conjunction with warfarin needs justiﬁcation. Half of the patients
in our study did not have an elevated (and therefore falsely
reassuring) INR but still presented with GI bleeding - nine of these
patients were co-prescribed an anti-platelet agent. A population-
based, retrospective case-control study by Delaney et al showed
that the risk of haemorrhage from the gastrointestinal tract was
greatly increased where anti-platelets and anti-coagulants were
combined.11 A recent Lancet Neurology review suggested that the0
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Fig. 4. Investigations used. Nine patients did not undergo further investigation due to
low severity of bleed, co-morbidities or frailty.only indications for combined anti-platelet and anti-coagulation
therapy are mechanical valves, AF with acute coronary syndrome,
and AF with recent percutaneous coronary intervention.2 None of
the 9 patients on warfarin and aspirin in our study matched these
criteria. A recent meta analysis has also shown that combining
aspirinwith warfarin is only indicated for patients with mechanical
heart valves, and that the risk of major bleeding is higher in this
situation in comparison to use of just aspirin or just warfarin.12 It
should be pointed out that there are no guidelines concerning the
use of warfarin and anti-platelets in combination.
The risk of becoming over anti-coagulated is clearly raised by
age and polypharmacy. Unsurprisingly, we found that patients with
a supra-therapeutic INR are more likely to suffer haemorrhage,
require transfusion and reversal agents. None of these patients
required any acute surgical intervention, and yet remained under
the care of the surgeons for their entire stay. We suggest that
patients who present with gastrointestinal haemorrhage be triaged
medically for treatment of coagulopathy and initial investigation.
Acute referral to a surgical team should only be made for large
bleeds or clinically unstable patients.
A large number of patients were not investigated because of
their age and co-morbidity, but where possible, further investiga-
tion should always be carried out as emphasised by the diagnosis of
4 previously occult neoplasms. It is essential that GI haemorrhage is
not dismissed as being secondary to over anti-coagulation only.
Diverticular disease was found in a number of patients and is
known to be more commonwith increasing age, with some studies
showing the prevalence to be as high as 60% in patients over 800
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Fig. 5. Length of hospital stay. The length of hospital stay for each patient.
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disease remain asymptomatic, around one-ﬁfth will suffer
complications, including haemorrhage.14 Anti-coagulant use has
been identiﬁed as a signiﬁcant risk factor for this and warfarin
should be used with caution in this group of patients.14
Excessive consumption of alcohol is known to affect warfarin
metabolism and lead to raised INRs. Documentation of this
important risk factor was poor in our study. A thorough social
history can identify underlying habits that may be causing over
anti-coagulation.
Various risk factors for warfarin associated bleeding have
previously been identiﬁed but no prediction rules for physicians
have been veriﬁed. The risk models that have been produced also
identify age and anti-platelet use as signiﬁcant variables, as well as
hepatic and renal impairment, and diabetes mellitus.15,16 However,
none of the patients in our study were found to have deranged liver
function tests on admission, though this does not rule out the
presence of liver dysfunction in these patients.
Ideally, data on all patients taking warfarin during the study
period should be collated as a denominator, and thosewho suffered
gastrointestinal bleeding should be compared with those who did
not, and hypothesised risk factors should be analysed – however,
this sort of data collectionwas not feasible, and thus our report is an
observational one only.
Warfarin is an important and useful drug. The evidence for
warfarin rather than aspirin in anti-coagulation is overwhelming.
When warfarin is not suitable, however, i.e. patients at high risk of
haemorrhage, it should certainly be considered. Aspirin at doses of
325 mg has been shown to signiﬁcantly reduce risk of stroke in
patients in atrial ﬁbrillation,17 especially in those aged less than 75
years. However, aspirin is not available in this dose in the United
Kingdom.6 The search for new alternatives to warfarin is ongoing.
Ximelagatran, a direct thrombin inhibitor, has been shown to be
superior to warfarin for post-operative prophylaxis of venous
thromboembolism18 and is as effective in the prevention of
stroke.19 Although the risk of bleeding complications with xime-
lagatran was not signiﬁcantly different to that with warfarin, there
are less dietary or pharmacological interactions, and the need for
continuous dose adjustment is avoided. However, the side effect of
hepatotoxicity has led to its discontinuation. Research into similar
drugs such as dabigatran is ongoing and there is also work
underway on other vitamin K antagonists such as acenocoumarol
and anti-platelet agents like triﬂusal, which is not available in the
UK. It is hoped the use of these newer agents may reduce the
complications and subsequent cost associated with warfarin use.
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